2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK
  5. CDK Isoform
  6. CDK Inhibitor

CDK Inhibitor

CDK Inhibitors (149):

Cat. No. Product Name Effect Purity
  • HY-137435
    Cirtuvivint
    		Inhibitor 98.28%
    Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research.
  • HY-14392
    5,6-Dichlorobenzimidazole riboside
    		Inhibitor 99.95%
    5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis.
  • HY-123937
    THAL-SNS-032
    		Inhibitor 99.16%
    THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).
  • HY-101467
    Trilaciclib
    		Inhibitor 99.20%
    Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy.
  • HY-144981
    HQ461
    		Inhibitor 98.07%
    HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.
  • HY-162001
    INX-315
    		Inhibitor 99.06%
    INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research.
  • HY-160701
    BLU-222
    		Inhibitor 99.02%
    BLU-222 is an orally effective and selective CDK2 inhibitor. BLU-222 has antitumor activity.
  • HY-144875
    CTX-712
    		Inhibitor 98.60%
    CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286).
  • HY-147054
    WEE1-IN-5
    		Inhibitor 99.90%
    WEE1-IN-5 is a potent WEE1 inhibitor with an IC50 value of 0.8 nM. WEE1-IN-5 inhibits phospho-CDC2. WEE1-IN-5 abrogates the G2 check point, increasing sensitivity to DNA damaging agents in cancer cells. WEE1-IN-5 can be used for researching anticancer.
  • HY-103019A
    (±)-Enitociclib
    		Inhibitor 99.87%
    (±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
  • HY-145669
    DIF-3
    		Inhibitor 98.07%
    DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression.
  • HY-W010128
    6-(Dimethylamino)purine
    		Inhibitor 99.79%
    6-(Dimethylamino)purine is a dual inhibitor of protein kinase and CDK.
  • HY-16297AS
    Abemaciclib-d8
    		Inhibitor 99.57%
    Abemaciclib-d8 is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
  • HY-102069
    3MB-PP1
    		Inhibitor 98.53%
    3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division.
  • HY-141687
    NSC 107512
    		Inhibitor 99.41%
    NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors.
  • HY-104013
    Aminopurvalanol A
    		Inhibitor 98.25%
    Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of Cyclins/Cdk complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization.
  • HY-150082
    CP681301
    		Inhibitor 99.18%
    CP681301 is a potent CDK5 inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila.
  • HY-15777AS
    Ribociclib-d6 hydrochloride
    		Inhibitor 99.24%
    Ribociclib-d6 (hydrochloride) is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].
  • HY-144995
    CDK4/6-IN-11
    		Inhibitor
    CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.
  • HY-128867
    bio-THZ1
    		Inhibitor 98.06%
    bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM.